Clinical Trial: KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07260812) titled 'KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma' on Nov. 21.

Brief Summary: This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with B-cell non-hodgkin lymphoma.

Study Start Date: May 07

Study Type: INTERVENTIONAL

Condition: Non-Hodgkin Lymphoma

Intervention: DRUG: KSV01 Injection

KSV01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries CD19 CAR.

Recruitment Status: RECRUITING

Sponsor: TCRx Therapeutics Co.Ltd

D...